These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29998370)

  • 21. Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study.
    Pallarés-Carratalá V; Ruiz-García A; Serrano-Cumplido A; Fragoso AS; Fernández-Pascual V; Sánchez-Sánchez B; Cervera-Pérez MI; Alonso-Moreno FJ; Arranz-Martínez E; Barquilla-García A; Rey-Aldana D; García JP; Cinza-Sanjurjo S;
    Clin Investig Arterioscler; 2024 Jun; ():. PubMed ID: 38910079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
    Fadini GP; Longato E; Morieri ML; Del Prato S; Avogaro A; Solini A;
    Lancet Reg Health Eur; 2024 Mar; 38():100847. PubMed ID: 38328413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.
    Watanabe Y; Kuribayashi N; Uchida D; Suzuki D; Kato M; Nagayama D; Ohashi H; Ohira M; Saiki A; Tatsuno I
    Diabetes Ther; 2019 Feb; 10(1):311-321. PubMed ID: 30574667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study.
    Alguwaihes AM
    Diabetes Ther; 2021 Jul; 12(7):1979-1992. PubMed ID: 34118010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of SGLT2 Inhibitors in Reducing Glycated Hemoglobin and Weight in Emirati Patients With Type 2 Diabetes.
    Bashier A; Khalifa AA; Rashid F; Abdelgadir EI; Al Qaysi AA; Ali R; Eltinay A; Nafach J; Alsayyah F; Alawadi F
    J Clin Med Res; 2017 Jun; 9(6):499-507. PubMed ID: 28496550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effect and rebound evaluation of dapagliflozin on glycated hemoglobin (HbA1c) in type 1 diabetes mellitus patients.
    Wang DD; Zhang C; Hu K; He SM; Zhu P; Chen X
    Front Pharmacol; 2022; 13():972878. PubMed ID: 36686651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Associated with the Remission of Type 1 Diastolic Dysfunction after Dapagliflozin Treatment in Patients with Type 2 Diabetes.
    Braha A; Albai A; Timar R; Diaconu L; Vasiluță L; Cipu D; Timar B; Sima A
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
    Evans M; Hicks D; Patel D; Patel V; McEwan P; Dashora U
    Diabetes Ther; 2020 Jan; 11(1):37-52. PubMed ID: 31813092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
    Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
    Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis.
    Fadini GP; Morales C; Caballero I; González B; Tentolouris N; Consoli A
    Diabetes Metab Syndr Obes; 2022; 15():3533-3541. PubMed ID: 36411790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'.
    Ptaszynska A; Cohen SM; Messing EM; Reilly TP; Johnsson E; Johnsson K
    Diabetes Ther; 2015 Sep; 6(3):357-75. PubMed ID: 26323372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.
    Bujac S; Del Parigi A; Sugg J; Grandy S; Liptrot T; Karpefors M; Chamberlain C; Boothman AM
    Diabetes Ther; 2014 Dec; 5(2):471-82. PubMed ID: 25502227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study.
    Morales C; Merino-Torres JF; Moreno-Moreno P; Lainez M; Tejado I; Yoldi A; Gutiérrez Medina S; Soto A; Botana MA; Bellido V; Caballero I
    Drugs Context; 2022; 11():. PubMed ID: 35251200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy.
    Huang Y; Lu W; Lu H
    Diabetol Metab Syndr; 2022 Mar; 14(1):47. PubMed ID: 35351189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Multinational Real-World Study on the Clinical Characteristics of Patients with Type 2 Diabetes Initiating Dapagliflozin in Southern Europe.
    Fadini GP; Tentolouris N; Caballero Mateos I; Bellido Castañeda V; Morales Portillo C
    Diabetes Ther; 2020 Feb; 11(2):423-436. PubMed ID: 31863344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study.
    Scott R; Morgan J; Zimmer Z; Lam RLH; O'Neill EA; Kaufman KD; Engel SS; Raji A
    Diabetes Obes Metab; 2018 Dec; 20(12):2876-2884. PubMed ID: 30019498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
    Mathieu C; Dandona P; Gillard P; Senior P; Hasslacher C; Araki E; Lind M; Bain SC; Jabbour S; Arya N; Hansen L; Thorén F; Langkilde AM;
    Diabetes Care; 2018 Sep; 41(9):1938-1946. PubMed ID: 30026335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
    Sakaeda T; Kobuchi S; Yoshioka R; Haruna M; Takahata N; Ito Y; Sugano A; Fukuzawa K; Hayase T; Hayakawa T; Nakayama H; Takaoka Y; Tohkin M
    Int J Med Sci; 2018; 15(9):937-943. PubMed ID: 30008607
    [No Abstract]   [Full Text] [Related]  

  • 40. Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes.
    Dawwas GK; Smith SM; Park H
    Diabetes Obes Metab; 2019 Jan; 21(1):28-36. PubMed ID: 30039524
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.